Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amphastar Pharmaceuticals Inc (AMPH) vs Conagra Brands Inc (CAG) Price & Performance

Amphastar Pharmaceuticals IncTrade
Conagra Brands IncTrade

Price performance (Past 24H)

Key statistics

Amphastar Pharmaceuticals Inc vs Conagra Brands Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Conagra Brands Inc trades at $15 (market cap $7.07B). The key difference: Conagra Brands Inc is far larger — about 8.2× Amphastar Pharmaceuticals Inc's market cap, and Conagra Brands Inc pays a 8.29% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

AMPHCAG
Market Cap
$863.95M$7.07B
Sector
HealthConsumer Staples
52-Week High
$30.81$20.02
52-Week Low
$16.87$12.58
Enterprise Value
$1.26B$14.12B
Dividend Yield
8.29%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amphastar Pharmaceuticals Inc

AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.

Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.

Conagra Brands Inc

Conagra Brands (CAG) trades at $15.11, up 1.75% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. Fundamentally, the company reported strong 2025 results with $11.6B revenue and $1.15B net income, but faces challenges with negative margins projected for 2026. Recent developments include a 50% dividend cut to $0.18 and new leadership appointments under CEO John Brase, who recently purchased 35,000 shares.

The outlook remains cautious despite attractive valuation metrics (P/E 10.06, P/S 0.64). While analyst consensus leans Hold (62.5%), the stock trades above the $13.67 target. Key risks include persistent inflation pressure, declining sales, and margin compression. The dividend reduction provides financial flexibility but signals ongoing turnaround challenges.

Returns comparison

Trailing returns across standard periods

About Amphastar Pharmaceuticals Inc

Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.

Read more on AMPH

About Conagra Brands Inc

Conagra Brands is a packaged food company that operates predominantly in the United States (over 90% of revenue and profits). It has a significant presence in the freezer aisle, with brands such as Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Other popular brands include Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, Wish-Bone, and Chef Boyardee. While the majority of revenue is sold into the U.S. retail channel, 9% of fiscal 2022 sales were to the food-service channel, down from 11% in fiscal 2019 due to the pandemic.

Read more on CAG